WORCESTER, Mass. and TORONTO, April 7, 2011 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) announced that this week there will be presentations of data from a clinical trial of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, at two international medical symposia.
The presentations, entitled "Use of Buccal Spray Insulin for Impaired Glucose Tolerance", will be given at the 4th International Congress on Pre-Diabetes and the Metabolic Syndrome in Madrid, Spain (April 6 – 9, 2011) and at the 7th Annual Clinical Diabetes Technology Meeting in Philadelphia, PA (April 8 – 9, 2011).
The abstracts, authored by Professor Paolo Pozzilli and Drs. Palermo, Napoli, Maddaloni, Lauria, Manfrini, Altomare, and Leotta, of the Endocrinology & Diabetes Department of University "Campus Bio-Medico" and the Diabetes Department of Hospital "S. Pertini", both in Rome, Italy, present study results demonstrating that patients treated with the Generex Oral-lyn™ buccal insulin spray achieved a significant reduction of HbA1c compared to the control group, with no adverse events.
These preliminary results suggest that the addition of Generex Oral-lyn™ can be an effective treatment compared to diet and physical exercise alone in patients with impaired glucose tolerance (IGT) in reducing HbA1c without adverse effects.
About Generex Biotechnology Corporation
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed int
|SOURCE Generex Biotechnology Corporation|
Copyright©2010 PR Newswire.
All rights reserved